NFL Biosciences

Regulatory Filings • May 29, 2024

NFL BIOSCIENCES : PRESENTATION OF THE STUDY RESULTS CONDUCTED WITH THE CEA AT THE ALBATROSS CONGRESS

Evidence of a new and disruptive mechanism of action in smoking cessation presented at France's leading addictology conference

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that the results of the study on the mechanism of action of its drug candidate NFL-101, conducted by the French Atomic Energy and Alternative Energies Commission (CEA), will be presented at the Albatros congress in Paris on June 5, 2024, one of the most important annual events in the treatment of addictology in France.

The 18th edition of the Albatros congress will be held in Paris from June 4 to 6, under the theme: "PREVENTION OR CURE: SHOULD WE CHOOSE? THE CHALLENGE OF ADDICTIONS TOMORROW". For this occasion, Dr. Nicolas Tournier, pharmacologist, radiopharmacist and head of the Pharmacological Neuroimaging team (BioMAPS Laboratory, CEA, Inserm, CNRS, Université Paris-Saclay), will present the results of the study he led on the central mechanism of action of NFL-101. This presentation will take place during the session about prevention, and will be entitled :

« Brain glucose metabolism as a readout of the CNS impact of cigarette smoke exposure, withdrawal, and the effects of NFL-101, as an immune-based druq candidate for smokinq cessation therapy ».

Nicolas Tournier commented: "I'm delighted to be presenting tesults of this study to addiction specialists. Beyond the NFL-101 results, this communication will also raise awareness among addiction clinicians of the potential of immunity as a new therapeutic weapon in the fight against tobacco addiction."

As a reminder, the aim of this study, which began in February 2023 and reported results in January 2024, was to use molecular imaging to explore the impact of the drug candidate on mice exposed to tobacco smoke, and to analyze the substance's effects on brain areas.

The study revealed that:

• NFL-101 has the ability to restore normal brain activity in the area of the brain often associated with the desire to smoke;
• The results suggest communication between the peripheral immune system and the central nervous system, a different mode of action from current smoking cessation drugs which directly target nicotinic receptors.

NFL-101 is a nicotine-free tobacco extract derived from a subcutaneous desensitization treatment that was initially developed by the Pasteur Institute against tobacco factory workers. NFL-101 has already been tested in two clinical trials: a Phase 1 study - CESTO - confirmed its safety and a Phase 2a study -PRECESTO - confirmed its ability to significantly reduce smoking satisfaction in smokers who do not want to quit. A Phase 2b clinical study - CESTO 2 - is underway at nine clinical centers in France with 318 smokers who wish to quit, with the results expected for July 2024.

Presided by Professor Amine Benyamina, Addictologist Psychiatrist and Professor at Paul Brousse University Hospital and President of the FFA (Fédération Française d'Addictologie) and RESPADD, a non-profit association of over 600 healthcare establishments involved in the prevention and management of addictive practices, the Albatros congress is one of the major events in the addictology treatment sector. For further information: https://congresalbatros.org/

About NFL Biosciences

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low-and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com

Contacts

Bruno Lafont – info@nflbiosciences.com - +33 4 11 93 76 67

Agence Calyptus – nflbio@calyptus.net - +33 1 53 65 68 68